Reported SAEs were predominantly gastrointestinal, particularly diarrhoea (1.6%) and vomiting (0.9%). Dehydration in association with diarrhoea was also notable. In the neratinib arm of study 3004 there were 4 cases of renal failure/acute renal failure associated with diarrhoea.